The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00224133 |
Recruitment Status :
Completed
First Posted : September 22, 2005
Results First Posted : April 27, 2010
Last Update Posted : April 27, 2010
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Benign Prostatic Hyperplasia | Drug: Silodosin | Phase 3 |
This will be a multi-center, open-label 40 week investigation in up to 1,200 men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, adverse events, concomitant medications, and compliance.
All subjects had previously participated in a 12-week double-blind placebo controlled trial (NCT000224107 or NCT000224120)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 661 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia |
Study Start Date : | September 2005 |
Actual Primary Completion Date : | April 2007 |
Actual Study Completion Date : | April 2007 |

Arm | Intervention/treatment |
---|---|
Experimental: Silodosin
Silodosin 8 mg per day with food
|
Drug: Silodosin
8 mg daily
Other Name: Rapaflo |
- Adverse Events [ Time Frame: 9 months ]All reported adverse events were recorded. Clinically significant abnormal laboratory values or other clinical findings upon examination were also recorded as adverse events.
- International Prostate Symptom Score (IPSS) [ Time Frame: 9 months ]The IPSS is a symptom severity scale from 0 to 35 that is derived from a 7 item questionnaire. 0 indicates no symptoms and 35 indicates most severe symptoms.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males in good general health and at least 50 years of age, who have completed SI04009 or SI04010.
Exclusion Criteria:
- Medical conditions that would confound the efficacy evaluation.
- Medical conditions in which it would be unsafe to use an alpha-blocker.
- The use of concomitant drugs that would confound the efficacy evaluation.
- The use of concomitant drugs that would be unsafe with this alpha-blocker.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224133

Study Director: | Lawrence Hill, Pharm D, RPh | Watson Pharmaceuticals |
Publications of Results:
Responsible Party: | Gary Hoel, RPh, PhD, Executive Director of Clinical Research, Watson Laboratories, Inc. |
ClinicalTrials.gov Identifier: | NCT00224133 |
Other Study ID Numbers: |
SI04011 |
First Posted: | September 22, 2005 Key Record Dates |
Results First Posted: | April 27, 2010 |
Last Update Posted: | April 27, 2010 |
Last Verified: | April 2010 |
benign prostatic hyperplasia, alpha blocker |
Prostatic Hyperplasia Hyperplasia Pathologic Processes Prostatic Diseases Silodosin Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists |
Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Urological Agents |